Biogen: Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe
TOKYO, Jan 11, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that Eisai has submitted a marketing authorization application (MAA) for lecanemab (Brand Name in the
New Zealand Mike Hencke Natacha Gassenbach Communications Department Investor Relations Department Drug Administration
Source: finanznachrichten.de